AbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira follow-up

16th August 2019 Uncategorised 0

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here. Friday, the FDA greenlighted Rinvoq, a rheumatoid arthritis med meant to succeed best-selling Humira as copycats bite into its sales. The new product should be available in the U.S. by late August, AbbVie said.

More: AbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira follow-up
Source: fierce